7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib
Camillo Porta(University of Pavia), Ilaria Imarisio(University of Pavia), Alessandra Bearz(Centro di Riferimento Oncologico), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Paglino, Manuela Schmidinger(Medical University of Vienna), Joaquim Bellmunt(Dana-Farber Cancer Institute), Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Aristotle Bamias(National and Kapodistrian University of Athens), Bohuslav Melichar(Palacký University Olomouc)
Cited by 7
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k